Abeona Therapeutics Inc.
ABEOAbeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing and delivering cell and gene therapies for life-threatening rare genetic diseases.
Table of contents
Earnings
Next report
Aug 13, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing and delivering cell and gene therapies for life-threatening rare genetic diseases. Its core value proposition centers on its proprietary manufacturing capabilities and the commercialization of the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company leverages specialized AAV capsid technology to target ophthalmic and other devastating conditions with high unmet medical needs.
Abeona holds a first-mover advantage in the RDEB market with the only FDA-approved autologous cell-based gene therapy for RDEB wounds.
Questions, answered.
- What is Abeona Therapeutics Inc.'s market cap?
- Abeona Therapeutics Inc. (ABEO) has a market capitalization of $405.8M and trades on NASDAQ.
- Who are Abeona Therapeutics Inc.'s competitors?
- Abeona Therapeutics Inc.'s key competitors include Krystal Biotech, Inc., Sarepta Therapeutics,, Inc. Common Stock, INmune Bio Inc. Common stock, and others. These companies compete in similar markets and product categories.
- Who does Abeona Therapeutics Inc. partner with?
- Abeona Therapeutics Inc.'s notable partners include Beacon Therapeutics, Ultragenyx Pharmaceutical Inc., Taysha Gene Therapies, Inc., and others.
- What subsidiaries does Abeona Therapeutics Inc. have?
- Abeona Therapeutics Inc.'s subsidiaries include Abeona Therapeutics LLC.
- Where is Abeona Therapeutics Inc. headquartered?
- Abeona Therapeutics Inc. is headquartered in United States of America and employs approximately 84 people. It has been publicly traded since 1980.